Literature DB >> 23301468

[Parkinson's disease combined with depression treated with electroacupuncture and medication and its effect on serum BDNF].

Yi Xia1, Hai-Dong Wang, Ying Ding, Bing Kang, Wei-Guo Liu.   

Abstract

OBJECTIVE: To verify the efficacy on Parkinson's disease combined with depression treated with electroacupuncture and medication and to explore the therapeutic mechanism.
METHODS: Sixty cases of Parkinson's disease combined with depression were randomized into an acupuncture + medication group and a medication group, 30 cases in each one. The conventional therapeutic program of oral administration of madopar and fluoxetine was applied in both groups. In the acupuncture + medication group, on the basic treatment as the above, electroacupuncture was applied to Baihui (GV 20), Yintang (EX-HN 3), Sishencong (EX-HN 1), Taichong (LR 3) and Sanyinjiao (SP 6), etc. The level of the serum brain-derived neurotrophic factor (BDNF) and the score of Hamilton depression scale (HAMD) were observed and compared before treatment and after 3 months of treatment. The efficacy was assessed in two groups.
RESULTS: The level of BDFN was improved significantly after treatment as compared with that before treatment in two groups (both P < 0.05) and the result in the acupuncture + medication group was superior to the medication group (P < 0.05). HAMD scores were reduced significantly after treatment as compared with those before treatment in two groups (both P < 0.05) and the result in the acupuncture + medication group was superior to the medication group (P < 0.05). The total effective rate was 90.0% (27/30) in the acupuncture + medication group, which was better than 83.3% (25/30) in the medication group (P < 0.05).
CONCLUSION: The combined therapy of electroacupuncture and medication achieves the significant efficacy on Parkinson's disease combined with depression. This therapy regulates effectively serum BDNF level, relieves depression symptoms of the patients. The efficacy of electroacupuncture combined with medication is superior to the simple medication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23301468

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  7 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Electroacupuncture for Cancer-Related Cognitive Impairment: A Clinical Feasibility Study.

Authors:  Yee Ran Lyu; Hye-Yoon Lee; Hyo-Ju Park; O-Jin Kwon; Ae-Ran Kim; In Chul Jung; Yang-Chun Park; Jung-Hyo Cho; Jung-Eun Kim; Mikyung Kim; Jun-Hwan Lee; Joo-Hee Kim
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

3.  Effect and Potential Mechanism of Electroacupuncture Add-On Treatment in Patients with Parkinson's Disease.

Authors:  Fang Wang; Li Sun; Xiao-Zhe Zhang; Jun Jia; Zhuo Liu; Xi-Yan Huang; Shu-Yang Yu; Li-Jun Zuo; Chen-Jie Cao; Xiao-Min Wang; Wei Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-13       Impact factor: 2.629

Review 4.  The neuroprotective role of acupuncture and activation of the BDNF signaling pathway.

Authors:  Dong Lin; Ike De La Pena; Lili Lin; Shu-Feng Zhou; Cesar V Borlongan; Chuanhai Cao
Journal:  Int J Mol Sci       Date:  2014-02-21       Impact factor: 5.923

5.  Electroacupuncture improves TBI dysfunction by targeting HDAC overexpression and BDNF-associated Akt/GSK-3β signaling.

Authors:  Shih-Ya Hung; Hsin-Yi Chung; Sih-Ting Luo; Yu-Ting Chu; Yu-Hsin Chen; Iona J MacDonald; Szu-Yu Chien; Peddanna Kotha; Liang-Yo Yang; Ling-Ling Hwang; Nae J Dun; De-Maw Chuang; Yi-Hung Chen
Journal:  Front Cell Neurosci       Date:  2022-08-09       Impact factor: 6.147

6.  A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.

Authors:  Lakkhina Troeung; Sarah J Egan; Natalie Gasson
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

7.  Electroacupuncture Alleviates Depressive-Like Symptoms and Modulates BDNF Signaling in 6-Hydroxydopamine Rats.

Authors:  Min Sun; Ke Wang; Yan Yu; Wen-Ting Su; Xin-Xin Jiang; Jian Yang; Jun Jia; Xiao-Min Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-07-25       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.